Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 3/20 | 0.41 |
| ▸ | EGFR | P00533 | 8/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | IGF1R | P08069 | 1/20 | 0.34 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 2/20 | 0.34 |
| ▸ | JAK2 | O60674 | 2/20 | 0.33 |
| ▸ | JAK3 | P52333 | 2/20 | 0.33 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.33 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24310153 | 0.93 | CTSC (0.36) | CTSCEGFRHRH4IGF1RMAP4K1 | |
| SCHEMBL24309916 | 0.89 | EGFR (0.39) | CTSCEGFRHRH4IGF1RMAP4K1 | |
| SCHEMBL24310715 | 0.87 | CSF1R (0.35) | CTSCEGFRHRH4IGF1RMAP4K1 | |
| SCHEMBL24310171 | 0.87 | CTSC (0.36) | CTSCEGFRHRH4IGF1RMAP4K1 | |
| SCHEMBL24310686 | 0.86 | BRD4 (0.38) | CTSCEGFRHRH4IGF1RMAP4K1 | |
| SCHEMBL24309810 | 0.86 | CTSC (0.47) | CTSCEGFRJAK2JAK3PTK2 | |
| SCHEMBL24310158 | 0.85 | MAP4K1 (0.37) | CTSCEGFRHRH4IGF1RMAP4K1 | |
| SCHEMBL24310404 | 0.85 | TACR1 (0.33) | CTSCIGF1RTACR1 | |
| SCHEMBL24309842 | 0.84 | CTSC (0.39) | CTSCEGFRIGF1RTACR1JAK2 | |
| SCHEMBL24309769 | 0.83 | MAP4K1 (0.32) | IGF1RMAP4K1PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022076627-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |